TD Cowen analyst Joseph Thome has maintained their bullish stance on VRDN stock, giving a Buy rating on November 9.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Joseph Thome’s rating is based on several promising developments within Viridian Therapeutics. The company is on the cusp of potentially significant milestones in 2026, including the anticipated approval of veligrotug for treating thyroid eye disease (TED) and the results from Phase III trials of VRDN-003. These advancements are bolstered by positive feedback from key opinion leaders, indicating strong potential for these therapies in the market.
Furthermore, Viridian’s lead candidate, veligrotug, has shown pivotal results that are at least on par with the current market leader, Tepezza, but with a more favorable administration profile. This could allow veligrotug to capture a significant share of the TED market. Additionally, VRDN-003 is designed for convenient at-home use, which may expand the treatment market and offer a competitive edge. Despite some regulatory and clinical risks, the company’s pipeline, including promising FcRn inhibitors, suggests a robust future, supporting the Buy rating.
According to TipRanks, Thome is a 5-star analyst with an average return of 11.4% and a 54.14% success rate. Thome covers the Healthcare sector, focusing on stocks such as United Therapeutics, AnaptysBio, and Alkermes.
In another report released on November 9, H.C. Wainwright also maintained a Buy rating on the stock with a $34.00 price target.